Drug intelligence / Profile preview

anti-D + intravenous immunoglobulin + methylprednisolone

Development stage
Unknown
Lead developer
CSL Behring
Modality
Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous, Oral, Intramuscular
01

Overview

This is a combination therapy consisting of three components: 1. **Intravenous Immunoglobulin (IVIG)**: A solution of human plasma proteins, particularly IgG antibodies with a broad spectrum of antibody activity. IVIG is prepared from large pools of human plasma collected from several thousand blood donors[7]. It strengthens the immune system's natural defenses by providing additional antibodies that help fight infections[1][2]. 2. **Methylprednisolone**: A synthetic glucocorticoid with anti-inflammatory properties. It's available in various formulations including oral tablets and injectable forms[8][9]. 3. **Anti-D Immunoglobulin**: Although not specifically detailed in the search results, anti-D is a specialized immunoglobulin that targets the Rhesus D antigen on red blood cells. This combination therapy is likely used for autoimmune conditions where multiple mechanisms of immune modulation are beneficial. IVIG provides antibody replacement and immunomodulation, methylprednisolone offers potent anti-inflammatory effects, and anti-D immunoglobulin provides targeted immune modulation.

02

Targets

C3b (Complement Component 3b)GR (Glucocorticoid receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on anti-D + intravenous immunoglobulin + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-D + intravenous immunoglobulin + methylprednisolone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call